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When breast screening began in the UK, such was 
the uncertainty concerning the beneﬁ ts and harms 
of detecting ductal carcinoma in situ (DCIS) that 
national guidelines speciﬁ ed an upper limit as well 
as a lower limit for detection by individual screening 
centres. This was only changed when an association 
was shown between DCIS detection and small invasive 
cancer detection in the National Health Service Breast 
Screening Programme.1 Nonetheless, controversy 
regarding the pros and cons of DCIS detection at 
screening has continued to this day.
In The Lancet Oncology, Stephen Duffy and 
colleagues2 make a major contribution to the debate 
concerning the benefits and harms of detecting DCIS 
at mammographic screening. The association between 
DCIS detected at screening and a reduction in invasive 
interval cancers in the subsequent 3 years shown in 
this study is novel and notable. The short time interval 
in which this effect is noted suggests that high-grade 
DCIS (which represents most screen-detected 
DCIS) has the potential to become invasive and 
symptomatic in a shorter time period than previously 
thought. However, this study has not addressed the 
effect of DCIS detection on invasive cancer detection 
at the subsequent screening round and beyond. Three 
previous randomised trials of breast cancer screening 
have shown that although the total number of cancers 
detected in the screening and control arms are similar, 
the frequency of invasive cancer is higher in the 
control group than in the screening group.3 Together, 
these studies suggest possible prevention of invasive 
disease by DCIS detection and treatment at screening.
The study by Duﬀ y and colleagues does not address 
the strong association seen between the grade of 
DCIS and the grade of invasive cancer arising from it, 
as shown in a previous report.4 The high sensitivity of 
mammography for high-grade DCIS with necrosis but 
low sensitivity for low-grade DCIS without necrosis5 
means that DCIS detection and treatment at screening 
will diﬀ erentially prevent the occurrence of high-grade 
invasive cancers. This should lead to beneﬁ ts in 
terms of breast cancer mortality reduction in a short 
period but not be associated with a high frequency of 
overdiagnosis. It is not clear if the high frequency of 
screen-detected HER2-positive high-grade DCIS leads 
to a reduction in HER2-positive invasive cancers in 
particular.6 
The results of this study do not mitigate the harms 
due to overdiagnosis caused by the detection of 
low-grade DCIS, which represents about 15% of 
screen-detected DCIS and 3% of all screen-detected 
cancer. The LORIS trial continues to be an important 
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future of cancer management, until such strategies 
become aﬀ ordable realities for most patients, the 
development of high therapeutic index chemotherapy 
regimens will remain one of the most important goals 
of academic oncologist societies. 
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Palliative sedation: more data and fewer opinions
Palliative sedation, initially named terminal sedation,1 
has become part of palliative care practice. The 
merit of the Article by Isseki Maeda and colleagues2 
published in The Lancet Oncology is to increase the 
quality of the evidence available regarding the eﬀ ect 
of continuous deep sedation on survival in order to 
support good clinical practice. Palliative sedation is 
deﬁ ned in scientiﬁ c documents and guidelines as 
the use of sedatives to reduce a patient’s level of 
consciousness with the aim of relieving symptoms due 
to a terminal illness that cannot be controlled by any 
other means.3,4
Inclusion of palliative sedation as an option in 
end-of-life decision-making processes in a series 
of articles based on retrospective questionnaires5 
answered by family doctors was problematic, because 
it (possibly unintentionally) allowed palliative sedation 
to be viewed as an alternative to euthanasia,5,6 although 
other authors have tried to make a clear-cut distinction 
between these two practices.7 Excessive emphasis on 
ethical discussions drawing on non-empirical evidence 
followed, and often confused the debate without 
contributing any clinical data. 
Despite opinion-based scientiﬁ c literature often 
stating otherwise, clinical experiences in palliative 
care show that pain is very rarely, if at all, a refractory 
symptom at the end of life; instead, the most frequent 
indications for palliative sedation are terminal 
dyspnoea and delirium. Additionally, the duration of 
palliative sedation is rarely longer than 24–48 h,8,9 
showing that many of the ethical concerns raised 
are based on fragile foundations. Yet the potential—
whether hypothetical or intended—life-shortening 
eﬀ ect of palliative sedation has been the central 
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study that aims to reduce the harms of detecting and 
treating low risk DCIS.7 Other indolent breast cancers 
detected at screening such as invasive tubular cancer 
deserve similar attention.
It has been argued that recalling for further 
assessment following screening only those patients 
with comedo calciﬁ cation and not those with 
granular calciﬁ cation might prevent overdiagnosis 
of low-grade DCIS while detecting high-grade DCIS. 
Unfortunately, when small, high-grade DCIS rarely 
shows the characteristic comedo calciﬁ cations seen 
in larger areas of high-grade DCIS, while a large area 
of low-grade DCIS might show comedo calciﬁ cation.8 
It is therefore impossible for radiologists to recall 
small cases of high-grade DCIS without also recalling 
low-grade DCIS. Although this study shows that sites 
with a high frequency of DCIS detection are associated 
with a higher proportion of low or intermediate grade 
DCIS, the eﬀ ect is very small. The smaller reduction of 
interval cancers associated with very high rates of DCIS 
detection is likely to be due to cases with small areas of 
high-grade DCIS having a longer time to invasion than 
cases of large areas of high-grade DCIS.
Further studies exploring how frequently DCIS 
detection at screening prevents biologically important 
invasive breast cancer are required for a full assessment 
of the beneﬁ ts and harms of detecting DCIS at 
mammographic screening.
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